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Abstract
Background: Diabetes Mellitus (DM) is a growing epidemic and the cost of treating diabetes is
largely increasing. The objective of this study was to estimate the cost-of-illness of DM among
attendees of out-patient clinics in Karachi, Pakistan. This is the first study conducted from a societal
perspective to estimate the cost of managing diabetes in Pakistan.
Methods:  A prevalence-based 'Cost-of-Illness' study for diabetes care was conducted in six
different out-patient clinics of Karachi, Pakistan from July to September 2006. A pre-tested
questionnaire was administered to collect the data from 345 randomly selected persons with
diabetes.
Results: The annual mean direct cost for each person with diabetes was estimated to be Pakistani
rupees 11,580 (US$ 197). Medicines accounted for the largest share of direct cost (46%), followed
by laboratory investigations (32%). We found that increased age, the number of complications and
longer duration of the disease significantly increase the burden of cost on society (p < 0.001).
Comparing cost with family income it was found that the poorest segment of society is spending
18% of total family income on diabetes care.
Conclusion:  This study concluded that substantial expenditure is incurred by people with
diabetes; with the implication that resources could be saved by prevention, earlier detection and a
reduction in diabetes co-morbidities and complications through improved diabetes care. Large
scale and cost-effective prevention programs need to be initiated to maximise health gains and to
reverse the advance of this epidemic.
Background
Diabetes Mellitus (DM) is a chronic and potentially disa-
bling disease. It is a major and growing threat to global
public health. The biggest impact of the disease is on
adults of working age; particularly in developing countries
[1]. The prevalence of diabetes and its adverse health
effects have risen more rapidly in South Asia than in any
other region of the world [2]. Diabetes significantly adds
to the burden of preventable diseases and leads to eco-
nomic losses that stem from high cost of care and loss of
productivity [3]. In South Asia the majority of people live
on or below the poverty line and having lack of access to
healthcare services, lack of national welfare schemes and
provision of health insurance for the poor population.
The poor people can not afford to pay for healthcare serv-
ices, hence they are diagnosed late with diabetes resulting
in acute and chronic complications [4]. The prevalence of
diabetes in Pakistan in the age group 20–79 years is 6.2
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million [5]; which indicates that over 11% of the adult
population are suffering from DM. Moreover, a similar
proportion of the population in Pakistan have impaired
glucose tolerance test (IGT) [6]; which is expected to rise
more rapidly in future.
DM is associated with a large variety of complications and
a greater risk of all manifestations of atherosclerosis [7].
Once diabetes develops, it is a costly disease to manage
because of its chronic nature and severity of complica-
tions [8]. Over 70% of diabetes related cost is attributed to
its complications, particularly for macro-vascular diseases
which most commonly occur in type 2 diabetics [4]. In a
multi-centre study from Pakistan Khuwaja et al, reported
that a substantial number of people with diabetes were
suffering with macro-vascular complications [7]. In India,
Ramachandran and colleagues reported that diabetes is
more common in the higher socio economic class while
diabetes complications are more prevalent among the
lower socio economic class [9]. When diabetes and its
complications affect the principal breadwinner; the
choice between healthcare expenses and food or clothing
can trap the whole family in a downward spiral of wors-
ening poverty and health [10].
Globally the direct healthcare cost of diabetes for people
in the 20 to 79 age group is estimated to be at least $153
billion annually [11]. Diabetes alone claims on average
around 8% of total health care budgets in developed
countries [12]. The healthcare cost of one diabetic patient
varies hugely between countries e.g. from US$ 13 in Bang-
ladesh to US$ 11,157 in the USA per year [13]. The eco-
nomic aspects of diabetes and its care continue to attract
attention as the world diabetes epidemic progresses and
health care systems remain under pressure to accomplish
more and more within constrained resources [11]. The
economic burden resulting from diabetes is a major con-
cern for many developed and developing countries. Med-
ical cost is two to three fold higher [14] and the economic
cost is two to five fold higher in people who have diabetes
compared to those without diabetes [15]. The increasing
healthcare cost is limiting healthcare resources all over the
world especially in developing countries. There is dire
need of urgent attention and action to initiate and aug-
ment prevention programs against this disease to reduce
the cost burden to society. The governmental and non-
governmental organizations NGO), diabetes associations,
health professionals and persons with diabetes them-
selves need to be aware of the current and future eco-
nomic impact of this disease on the individual, family,
society and healthcare institutions [11].
Studies on the cost of diabetes are scanty in the South
Asian region. In Pakistan no such study has been docu-
mented to calculate the cost of diabetes. In this era of
scarce resources and rising cost, it is critical to have an
understanding of the economic aspect of diabetes in order
to develop and implement sound public health and pre-
vention policies. This cost-of-illness study aimed to esti-
mate the economic burden of diabetes in Karachi,
Pakistan from the societal perspective.
Methods
A prevalence-based "Cost of Illness" study design was
used to estimate the cost of diabetes care in different out-
patient clinics of Karachi, Pakistan. Karachi, a city of more
than 15 million inhabitants, is the largest metropolitan
city and is considered a leading industrial, commercial
and financial hub of Pakistan [16].
At the core, cost of illness estimates represent a descriptive
economic method [17] which is most often used to esti-
mate the cost of a particular disease. This study was carried
out in six different out-patient clinics at three selected sites
in Karachi representing public, private and NGO provi-
sion. From each setting, two clinics including diabetes
management and family practice/general medicine/inter-
nal medicine were selected. Further, it was assumed that
all levels of socio-economic status (SES) would be cap-
tured in these clinics. Diabetic subjects who fulfilled the
eligibility criteria were selected using systematic random
sampling technique from the six out-patient clinics at the
three sites i.e. two clinics from each site. The data was col-
lected from July 2006 to August 2006 by trained data col-
lectors.
A total 353 eligible subjects were approached based on a
proportionate attendance of patients in the different stud-
ied clinics. Informed consent was taken prior to conduct-
ing the interview from each study subject. We intended to
approach all the persons with diabetes (type 1 and type 2)
however in random selection no person was found with
type 1 diabetes; hence all the study subjects were with type
2 diabetes. From all randomly selected subjects, 345 (98%
response rate) were found willing to participate in the
study. The subjects excluded from the study were patients
with pregnancy; people less than 20 years or more than 60
years of age; and those who were diagnosed as diabetic in
the current visit (i.e. newly diagnosed). Taken to be the
most productive years, subjects in the age range 20–60
years were recruited in the study. A structured pre-tested
questionnaire was used to collect the information on
socio-demographic and clinical characteristics (see addi-
tional file 1). These variables were also checked and veri-
fied from the medical records of patients. All subjects were
asked about direct and indirect health care costs. Some
costs were imputed to reflect opportunity cost. Indirect
healthcare cost was calculated using the human capital
approach; here average wage rates/replacement costs were
used to impute values. The human capital approach con-BMC Health Services Research 2007, 7:189 http://www.biomedcentral.com/1472-6963/7/189
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siders the value of lost productivity as a result of disability
and premature death, using lost earnings as a surrogate for
the impact that premature death and disability had on
individuals and society [18]. Data on indirect costs cov-
ered in this study include the cost for loss of productivity
and loss of time (during travelling, waiting in clinic and
consultation). The cost for lost productivity has been esti-
mated (for office job employees, businessmen, laborers
and housewives) by using respective wage rate per hour.
The Pharmacy guide [19] for the year 2004 was used to
calculate the cost for medicines. SES was obtained using
criteria (based on household items) of National Health
Survey of Pakistan (NHSP) [20]. The wage rate of house-
wives was estimated using minimum wage rate of Paki-
stan (Rs. 16.7/- per hour) [21]. Costs were measured in
Pakistani Rupee; to express costs in terms of international
currency we applied a rate of Rs. 60 per US$.
Perspective
Perspective is important because it determines the types of
costs to be included in the study. This cost of illness study
has been conducted from the societal perspective. Adop-
tion of the societal perspective facilitates policies aimed at
maximizing the welfare gains to society, or minimizing
the losses.
Ethical approval
Ethical approval was taken from the Ethical Review Com-
mittee (ERC) of the Aga Khan University (AKU). Written
permission was sought from all clinical administrators
and written informed consent was taken from individual
study subjects. All literate individual subjects read the
consent paper by themselves and signed. For the illiterate
subjects, the data collector read and translated the consent
paper to them and if they agreed, their thumb impression
or sign was taken.
Data management and analysis
Data were validated after double entry and then analyzed
on the Statistical Package for the Social Sciences (SPSS)
version 14. Mean and standard deviations were calculated
for all the cost variables. For association of outcome with
independent variables, univariate analysis was carried out
by 'Kruskal Wallis' and 'Mann Whitney U' tests with a sig-
nificance level of 5%. For this analysis, cost variables were
categorized as appropriate and mean cost was compared
between the categories of independent variables. The costs
for subsidized services at public and charitable healthcare
providers were imputed using the approximate average
cost for respective services. Indirect healthcare costs for
study subjects and their accompanying persons were cal-
culated using the human capital approach.
Results
Socio-demographic and clinical characteristics
A total of 345 persons with diabetes were interviewed
with mean (SD) age 48.12 (9.12). A Majority (64%) of
study subjects were female and only 18% of subjects had
graduated or having higher level of education. By occupa-
tion, the majority (55%) were housewives and only
(17%) were employed in office job or having their own
business. Of the total, about (48%) had a household
income ranges between Rs. 5,001 – 20,000. Using NHSP
criteria, we found that about 60% of households would be
of middle SES, with 7% and 33% of households catego-
rized as low and high SES respectively. A larger group of
the respondents (73%) were treating their diabetes with
oral medication while (21%) and (6%) were treating their
diabetes with insulin and lifestyle modification respec-
tively. A majority of subjects (72%) had one or more dia-
betes related co-morbidity (Table 1).
Table 1: Distribution of socio-demographic and clinical 
characteristics among persons with diabetes attended different 
diabetes clinics in Karachi, Pakistan (n = 345)
Characteristics Number Percentages
Age
20 – 40 years 90 26.1
41 – 50 years 124 35.9
51 – 60 years 131 38.0
Sex
Male 126 36.5
Female 219 63.5
Education
Illiterate 102 29.6
Up to primary 74 21.4
Secondary to intermediate 107 31.0
Graduate and above 62 18.0
Employment status
Jobless 40 11.6
Laborer 56 16.2
Housewife 190 55.1
Office job/businessman 59 17.1
Monthly household income
Up to 5000 82 23.8
5001 – 20000 165 47.8
> 20000 98 28.4
Socioeconomic status (SES)
Low SES 23 6.7
Middle SES 208 60.3
High SES 114 33.0
Duration of diabetes
1–5 years 185 53.6
6–10 years 87 25.2
>10 years 73 21.2
Mode of treatment
Lifestyle modification 20 5.8
Oral medication 252 73.0
Insulin 73 21.2
Co-morbidities
No co-morbidity 97 28.1
1 co-morbidity 81 23.5
>1 co-morbidity 167 48.4BMC Health Services Research 2007, 7:189 http://www.biomedcentral.com/1472-6963/7/189
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We focused on the use of resources for the one out-patient
visit including costs of consultation, investigation, medi-
cation, travel and food costs. We found that on average
each patient visited every second month, hence this cost is
calculated for one visit (two months approximately).
More specifically, to estimate costs subjects were asked the
number of times they visited the doctor per year. A more
detailed response was required for medications so the last
month was used; which included questions on dose, fre-
quency and expenditure. All other costs were based on the
current visit and extrapolated.
Direct and indirect cost of diabetes care
In the current visit the mean cost for consultation with a
physician, laboratory investigations and medicines came
to Rs. 205, 516 and 748 respectively. The mean cost for
travel and food incurred was Rs. 120 and 33 respectively.
From the total diabetes cost components, the cost for
medicine represents the largest share (46%), followed by
laboratory cost (32%). The unit cost has been estimated in
terms of mean cost per visit for each of the cost variable.
Total mean direct cost borne by the person with diabetes
and/or his/her family is estimated to be Rs. 1,930 in the
current visit. The value for lost productivity was calculated
based on the average earnings of those whose productivity
was forgone. Excluding unemployed persons, the mean
lost productivity by study subjects and their attendants
was Rs. 113 and 208 respectively and their mean time lost
was 3 hours. We found that overall the mean economic
cost borne by each person with diabetes and/or his/her
family came to Rs. 2,070/- for each visit. Adjusting this
cost to monthly and yearly basis, it amounts to Rs. 1,035/
- and 12,420/- respectively (data not shown) (Table 2).
Correlates of cost of care
The mean (SD) direct costs were higher for males com-
pared to females (1,743 vs. 1,555) although the difference
was not significant (p = 0.132), however the indirect cost
was significantly higher for males compared to females
(males: 298; females: 86; p < 0.001). Considering age, the
direct cost was marginally higher amongst the older age
group compared to younger age groups (p = 0.06). The
more educated study subjects expended more on diabetes
care and this difference was significant (p < 0.001). By
monthly family income, the direct and indirect cost was
greater for the higher income families compared to lower
income families and this difference was also significant (p
< 0.001). Persons of higher SES were spending more as
compared to those of lower SES and this difference was
found to be significant for both direct (p < 0.001) and
indirect (p < 0.001) costs (Table 3).
For clinical characteristics, duration of diabetes, and
number of co-morbidities were analyzed with reference to
Table 2: Direct and indirect cost in Pakistani Rupee of studied persons with diabetes per visit
Variables Mean (SD)
Direct cost
Consultation cost 205.1 (277.3)
Investigations cost 515.8 (809.7)
Medicine cost 748.0 (682.9)
Travel cost 119.7 (232.6)
Food on way to clinic cost 33.2 (56.6)
Subsidized consultation cost for public hospital based clinics and welfare clinic* N** 201.7 (- -)
Subsidized investigation cost for public hospital based clinics and welfare clinic* N** 494.0 (- -)
Indirect cost
Lost time (patients)
Office employees/businessmen 3.5 (4.0)
Laborers 3.2 (2.2)
Housewives 2.8 (1.7)
Lost productivity (patients) ^†
Office employees/businessmen 363.2 (576.3)
Laborers 73.4 (102.0)
Housewives‡ 46.1 (27.8)
Lost time (attendants)
Office employees/businessmen 3.1 (3.6)
Laborers 3.1 (1. 8)
Loss of productivity (attendants) #
Office employees/businessmen 268.1 (578.5)
Laborers 54.9 (30.1)
• Subsidized consultation and investigation cost is calculated using approximate average of overall respective charges
• ** N = 152, ^N = 305, #N = 67
• † Lost productivity has been estimated by using specific wage rate per hour
• ‡ The wage rate of housewives was estimated using minimum wage rate of PakistanBMC Health Services Research 2007, 7:189 http://www.biomedcentral.com/1472-6963/7/189
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the cost of diabetes care between groups. Mean (SD) direct
cost of persons with diabetes with duration of illness
between 1–5 years was Rs. [1,413 (1,426)]; 6–10 years
was [1,680 (1,518)]; and >10 years was [2,090 (1,774)];
and the cost difference was significantly higher among
persons with a longer duration of diabetes (p = 0.006),
however the indirect cost difference between these groups
was not significant (p = 0.824). The mean (SD) direct cost
in persons having no co-morbidity was Rs. [1,226
(1,328)] and those having one or more co-morbidities
was [1,779 (1,600)] and this difference was significant (p
= 0.006) between groups, while the difference for the indi-
rect cost between these groups was not found significant
(p = 0.583). Comparing the mode of treatment with direct
cost, we found significant difference (p < 0.001) between
those with non-pharmacological lifestyle management to
oral medication and insulin, while indirect cost was not
significant (p = 0.950) (Table 3).
Discussion
Diabetes is a costly disease to manage and its cost affects
individuals, families, society, healthcare institutions and
national productivity. This is the first documented study
on the cost of diabetes care conducted in Pakistan. In this
study, every possible effort was made to incorporate the
majority of cost components associated with diabetes
care. Decision-makers are mostly interested in untrans-
formed cost analysis [22] hence we analyzed the untrans-
formed diabetes care cost. However, decision-makers have
to allocate resources in the context of scarcity and compe-
tition with other sectors (housing, education, etc). Fur-
ther, it will always be a question as to whether resources
are efficiently and effectively allocated. Economic analysis
can make an important contribution to the efficient allo-
cation of scarce resources.
This study has produced some important key findings
related to the economics of diabetes that may contribute
Table 3: Socio-demographic and clinical characteristics correlated with cost of diabetes management among study subjects*
Direct cost Indirect cost
Characteristics Mean (SD) p. value Mean (SD) p. value
Socio-demographic characteristics
Age
20 – 40 years 1477.6 (1555.7) 0.06 153.1 (402.3) 0.142
41 – 50 years 1527.7 (1549.5) 150.9 (362.5)
51 – 60 years 1814.6 (1530.6) 157.4 (478.4)
Sex
Male 1742.8 (1569.7) 0.132 298.2 (699.3) < 0.001
Female 1555.0 (1533.0) 86.0 (111.2)
Education
Illiterate 746.7 (607.7) < 0.001 55.2 (44.4) 0.004
Up to primary 1612.8 (1735.2) 162.6 (579.5)
Secondary to intermediate 1713.4 (1431.7) 155.6 (233.7)
Graduate and above 2923.9 (1642.7) 300.5 (639.6)
Monthly household income
Up to 5000 673.8 (575.9) < 0.001 51.6 (34.5) < 0.001
5001 – 20000 1354.0 (1314.4) 90.0 (132.0)
> 20000 2843.0 (1688.4) 332.6 (712.3)
Socio-economic status (SES)
Low SES 855.0 (618.1) < 0.001 61.0 (47.7) < 0.001
Middle SES 1010.0 (1063.5) 78.2 (115.5)
High SES 2898.1 (1638.9) 300.8 (670.2)
Clinical characteristics Duration of DM
1–5 years 1412.9 (1425.9) 0.006 167.2 (479.4) 0.824
6–10 years 1680.1 (1517.7) 136.9 (178.7)
> 10 years 2090.0 (1773.9) 138.6 (442.6)
Mode of treatment
Lifestyle modification 1302.0 (1163.9) < 0.001 181.7 (174.3) 0.950
Oral medication 1373.6 (1434.9) 153.0 (424.5)
Insulin 2574.7 (1546.1) 148.2 (443.3)
Co-morbidities
No co-morbidity 1226.2 (1327.7) 0.006 165.2 (420.5) 0.583
≥ 1 co-morbidity 1779.0 (1600.3) 149.5 (415.7)
* All costs are measured in the Pakistani Rupee and for international currency, we considered Rs. 60 per US$.BMC Health Services Research 2007, 7:189 http://www.biomedcentral.com/1472-6963/7/189
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to better healthcare planning. It indicates how much soci-
ety is spending on diabetes care, which can then be
weighted against the cost of implementing prevention
programs. Once the diabetes develops then it needs to be
controlled to avert the co-morbidities and complications,
which can again cause significant cost. Secondly, this
study has recognized the cost of diabetes care in relation
to different socio-demographic and clinical characteris-
tics. On average one person with diabetes spends Rs. 965
(direct cost only) per month. The overwhelming cost of
diabetes threatens to stunt economic growth and under-
mine the standard of living. Thirdly, it identified the
diverse components of cost and the magnitude of the con-
tribution of each component. In some clinics costs (con-
sultation and laboratory investigations) were subsidized,
hence a level of subsidy was calculated using approximate
average for consultation and laboratory investigations
services. This research has been carried out using the soci-
etal perspective, which is usually preferred for public
health decisions because all the costs including direct,
indirect and intangible costs and all resources and bene-
fits, regardless of who pays for or who receives them, are
included in the analysis.
The results of this cost of diabetes care study cannot be
matched with other studies conducted in developed coun-
tries [15,23], mainly because of social and economic dif-
ferences. Studies on the total cost of diabetes in
developing countries are few and of the cost analyses
undertaken different techniques have been used, making
attempts of comparison problematic.
On socio-demographic factors, higher monthly income
and higher education were found positively correlated
with increased diabetes cost in this study. Significant cor-
relation with educational status has been reported by
other studies conducted in India [24,25]. This may be
because of more awareness of disease with higher educa-
tional status and that more educated people earn more;
hence can afford more for their health. It is well estab-
lished that the cost of managing diabetes is dominated by
old age [26-28], a phenomenon supported by this study.
This study highlights that the direct cost is higher in per-
sons with diabetes of longer duration and one or more co-
morbidities and complications. This pattern was also
observed in other studies conducted both in developing
[24,29] and developed countries [27]. Complications
escalate the cost of managing disease and diabetes is asso-
ciated with many complications, which will ultimately
impact on the healthcare system. Likewise longer duration
of the disease makes the condition worse which eventu-
ally results in higher treatment cost.
In this study, the largest component of total direct health-
care cost was accounted for was medicines followed by
laboratory investigations. Excluding hospitalization costs
similar findings have been reported in some other studies
conducted in developed [14,23,27] as well as developing
countries [30]. Overall, the mean direct cost exhibits a
positive relationship with the mean income of the family.
We found that for persons earning ≤ Rs. 5,000/-, their
mean direct cost for treating the diabetes was 18.4% of
their mean total income. This is comparable with a study
conducted in India, where those on low incomes devote
25% of family income on diabetes care [30].
None of the person with diabetes indicated that their cost
is borne by an insurance company or their employer.
Almost all the cost is out-of-pocket; from individual or
family income. This is not exactly similar to some other
studies but Grover and colleagues reported that 95% of
cost is met by patients and their families in India [24]. In
this part of the world where social protection is virtually
non-existent and most expenses are out-of-pocket [31],
there is a strong need to develop different health insur-
ance schemes especially for the poorer segment of the
population in order to protect their household budget
and increase treatment compliance, which will help pre-
vent unnecessary complication(s).
Considering the current prevalence of diabetes in Paki-
stan, if only the direct cost of diabetes care for out-patient
management clinic is calculated, it will be more than Rs.
71 billion for one year. This is 80% greater than the total
national health budget (Rs.40 billion) for the current fis-
cal year. The estimated cost may be termed here as the
minimum economic cost of diabetes care in out-patient
clinics of Pakistan. These figures would be even higher if
hospitalization costs and the costs related to old age (> 60
years) of persons with diabetes were included. Determin-
ing the cost of a particular disease is claimed to provide
useful information for health policy making and it is
argued that such information can help nations to deter-
mine research and funding priorities by highlighting areas
where inefficiencies may exist and savings could be made
[32].
Conclusion
There is a dearth of disease based economic studies in
developing countries and in Pakistan no such study has
previously been documented. The estimates here provide
information about the use of resources related to diabetes
and help to describe the impact that society faces from
such a disease. This initial study can lead to further inves-
tigations in which cost-effective interventions could be
evaluated leading to a potential reduction in the eco-
nomic burden of diabetes.BMC Health Services Research 2007, 7:189 http://www.biomedcentral.com/1472-6963/7/189
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In this study, there are some limitations, which should be
considered before generalizing the results. First, the inclu-
sion criteria were restricted to out-patients and the 20–60
years age group, also the major cost burden may be attrib-
utable to hospitalisations amongst older persons with the
disease. Second, the cost of self monitoring of glucose lev-
els was not included. Third, the lost productivity of study
subjects and their attendants who were unemployed was
not considered.
Nevertheless the information is sufficient enough to make
some recommendations. For instance, that easily accessi-
ble and affordable healthcare service is required for all
persons with diabetes. Availability and affordability of
services and drugs can help these people to get the
required healthcare services to manage their diabetes. Pol-
icy makers need to ascertain the priority of prevention
programs at primary healthcare outlets and they also need
to ensure the availability of effective patent anti-diabetic
drugs at cheaper rates to reduce the medication cost com-
ponent. The latter must be done without compromising
the quality of care. Furthermore, pharmaceutical compa-
nies should be encouraged to produce better quality and
lower-priced drugs for patients with diabetes.
There is a need to promote more research at a national
level on disease-based economic studies to know precisely
the social, financial and economic burden of disease in
order to inform policy. This would complement interna-
tional level evidence generated through the WHO-
CHOICE project on the costs, impact on population
health and cost-effectiveness of various health interven-
tions. More specifically, however, research is needed to
identify such cost-effective interventions that will not only
lessen the cost of diabetes but improve the overall health
status of the persons with diabetes. In addition, healthcare
providers need to update themselves on current disease
knowledge and best medical practice for better manage-
ment of diabetes. In particular, this will facilitate preven-
tive strategies and help control the condition through
rational prescribing and investigations.
The economic burden of diabetes care is prompting con-
cern throughout the world. Facing the challenges brought
about by the epidemic of diabetes, agencies/authorities
(NGOs, private and public) will need to work closely if
the burden is to be reduced.
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